罗格列酮治疗原发性高血压合并2型糖尿病疗效观察

The curative effect of rosiglitazone on the primary hypertension patients with Type 2 diabetes mellitus

目的:探讨罗格列酮治疗原发性高血压合并2型糖尿病的降压疗效。方法:将106例原发性高血压合并2型糖尿病患者随机分为观察组与对照组,每组53例,对照组给予降压药或注射胰岛素控制血糖,加用苯那普利10～20mg/d;观察组则在对照组的基础上加用罗格列酮15mg/d,两组12周为1个疗程,并监测血压。结果:观察组总有效率为94.34%,对照组为73.58%,两组相比差异有统计学意义(P<0.05)。结论:罗格列酮治疗原发性高血压合并2型糖尿病安全有效,降压作用较强,有明显的肾脏保护作用。

Objective：To discuss the curative effect of rosiglitazone on the primary hypertension patients with Type 2 diabetes mellitus.Methods：106 cases primary hypertension with Type 2 diabetes mellitus patients were randomly divided into observation group and control group,every group for 53 cases,the control group was treated with hypotensor or injecting the insulin to be control of blood glucose,added benazepril 10-20 mg for one.On the basis of the control group,the observation group was treated with rosiglitazone 15 mg for one day.One course period of treatment was 12 weeks,and observed the blood pressure.Results：The total effective rate of the observation group was 94.34 percent,the control group was 73.58 percent,there was statistical significance between the two groups（P〈0.05）.Conclusion：The rosiglitazone on the primary hypertension patients with Type 2 diabetes mellitus is safe,and the hypotensive action is powerful,it can protect the kidney.